The Suzhou toxicology facility of WuXi PharmaTech obtained the statement of Good Laboratory Practice (GLP) from the Organization for Economic Cooperation and Development (OECD). The inspection was conducted by the Belgium GLP Monitorate.
The inspection was made on 22 studies including toxicology, genetic toxicology, safety pharmacology, dermal irritation, skin phototoxicity, and immunology.
Dr. Ge Li, CEO of the company, said ‘with this recognition, WuXi has further solidified its leadership in offering the highest-quality toxicology service in China’.
Source: TrueblueTribune Publication Date: 2014-05-30